Source-grounded facts extracted from Profound Medical Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Profound Medical Corp. reported the first quarter ended March 31, 2026 results: revenue $5.3 million, net income $7.0 million, EPS $0.19 per common share. Guidance initiated.
“For the quarter ended March 31, 2026, Profound recorded revenue of approximately $5.3 million”
Profound Medical Corp. entered into Subscription Agreement with certain Canadian investors valued at aggregate gross proceeds of $6.45 million (effective 2025-12-30).
“On December 30, 2025, Profound Medical Corp. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with certain Canadian investors (the “Investors”) providing for the private placement of an aggregate of 921,428 shares of the Company’s common shares (the “Shares”), at a per share purchase price of $7.00 (the “Offering”) for aggregate gross proceeds of $6.45 million.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.